PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies Ke Xin LinAlexandra C. IstlXiufen Zheng Review Open access 13 October 2023 Pages: 3875 - 3893
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers Liya ZhuXiu Juan LiByeong-Cheol Ahn Review 05 October 2023 Pages: 3895 - 3917
Human anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolism Hari OmUmesh ChandPramod Kumar Kushawaha Review 26 October 2023 Pages: 3919 - 3930
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents Maria Livia Del GiudiceSara GalimbertiGabriele Buda Review Open access 04 November 2023 Pages: 3931 - 3937
Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer Ningjing LiDavendra Sohal Review 23 November 2023 Pages: 3939 - 3952
The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma Liqiu KouXiaolu XieYaling Li Review 02 November 2023 Pages: 3953 - 3969
Organ-on-a-chip models for development of cancer immunotherapies M. ChernyavskaM. MasoudniaW. P. R. Verdurmen Review Open access 03 November 2023 Pages: 3971 - 3983
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion Kumaravel MohankumarGus WrightStephen Safe Research Open access 17 October 2023 Pages: 3985 - 3999
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion Mussarat WahidBenjamart PratoomthaiDavid O. Bates Research Open access 16 November 2023 Pages: 4001 - 4014
XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models Bochun WangYujie LiuXin Gao Research 21 October 2023 Pages: 4015 - 4030
Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies Yan LuoYaqing QieHong Qin Research 10 October 2023 Pages: 4031 - 4047
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition Mick J. M. van EijsRik J. Verheijdenthe UNICIT consortium Research Open access 04 October 2023 Pages: 4049 - 4064
An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response Didem Naz DiokenIbrahim OzgulAyse Elif Erson-Bensan Research 28 September 2023 Pages: 4065 - 4075
Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis Qingting HuangJiyi HuLin Kong Research Open access 30 September 2023 Pages: 4077 - 4088
Intensified NK cell therapy in combination with low-dose chemoradiotherapy against human colorectal cancer Huy Phuoc Quang NguyenWoo Kyun BaeMeesun Yoon Research 06 October 2023 Pages: 4089 - 4102
A modified immune cell infiltration score achieves ideal stratification for CD8+ T cell efficacy and immunotherapy benefit in hepatocellular carcinoma Banglun PanYue LuoNanhong Tang Research 27 September 2023 Pages: 4103 - 4119
Correction to: A modified immune cell infiltration score achieves ideal stratification for CD8+ T cell efficacy and immunotherapy benefit in hepatocellular carcinoma Banglun PanYue LuoNanhong Tang Correction 16 November 2023 Pages: 4121 - 4122
Apolipoprotein C-III itself stimulates the Syk/cPLA2-induced inflammasome activation of macrophage to boost anti-tumor activity of CD8+ T cell Xiangyu HuShizhen DingXiaoqin Jia Research 18 October 2023 Pages: 4123 - 4144
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1 Karin Enell SmithSara FritzellPeter Ellmark Research Open access 05 October 2023 Pages: 4145 - 4159
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study Qi FangPengfei XuXuekui Liu Research 07 October 2023 Pages: 4161 - 4168
The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients Izabela ChmielewskaAnna GrendaJanusz Milanowski Research Open access 10 October 2023 Pages: 4169 - 4177
A novel CD47-blocking peptide fused to pro-apoptotic KLA repeat inhibits lung cancer growth in mice Linyue PanLu HuZhilong Jiang Research 13 October 2023 Pages: 4179 - 4194
Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor Derrick McCarthyMichael LofgrenRobert Tighe Research Open access 18 October 2023 Pages: 4195 - 4207
Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity Pengfei XuQi FangXuekui Liu Research 14 October 2023 Pages: 4209 - 4219
The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression Nicola E. AnnelsM. DenyerHardev Pandha Research Open access 08 November 2023 Pages: 4221 - 4234
The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer Ziyun ShenMeixin TengPeng Zhang Research 06 November 2023 Pages: 4235 - 4247
Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression Zijie LiYuehua ZhangZhiyu Wang Research 09 November 2023 Pages: 4249 - 4259
Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome Aliva Prity MinzDebasish MohapatraShantibhusan Senapati Research 05 November 2023 Pages: 4261 - 4278
BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex Bowen YaoYe LuDemao Yao Research Open access 31 October 2023 Pages: 4279 - 4292
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer Qin HuRuntian WangBo Ding Research 31 October 2023 Pages: 4293 - 4308
Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren’s syndrome Philine Witkowski Durand VielKim HenryPhilippe Guilpain Research 08 November 2023 Pages: 4309 - 4322
Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model Dashuai YangYu ZhouYouming Ding Research 25 November 2023 Pages: 4323 - 4335
GPC3 and PEG10 peptides associated with placental gp96 elicit specific T cell immunity against hepatocellular carcinoma Lijuan QinJiuru WangSongdong Meng Research Open access 06 November 2023 Pages: 4337 - 4354
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs Ruoxue CaiYing LiuBo Shen Research Open access 31 October 2023 Pages: 4355 - 4365
HPV-associated head and neck cancer is characterized by distinct profiles of CD8+ T cells and myeloid-derived suppressor cells Benjamin A. KansyTim P. WehrsSven Brandau Research Open access 29 November 2023 Pages: 4367 - 4383
Spatial immune composition of tumor microenvironment in patients with pancreatic cancer Eline S. ZwartThomas van EeGeert Kazemier Research Open access 08 November 2023 Pages: 4385 - 4397
Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia Qian PengRenhua HuangZhitao Wang Research 06 November 2023 Pages: 4399 - 4414
Unraveling intratumoral complexity in metastatic dermatofibrosarcoma protuberans through single-cell RNA sequencing analysis Ling-Ling GeZhi-Chao WangQing-Feng Li Research 08 November 2023 Pages: 4415 - 4429
Tumor immunology meets oncology (TIMO) XVII, April 20–22 2023 in Halle/Saale, Germany Barbara Seliger Meeting Report Open access 23 October 2023 Pages: 4431 - 4439
Cholesterol induction in CD8+ T cell exhaustion in colorectal cancer via the regulation of endoplasmic reticulum-mitochondria contact sites Han ShuwenWu YinhangYang Xi Brief Report 03 November 2023 Pages: 4441 - 4456
An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1 Haibin DengHuixiang GeThomas Michael Marti Methodology Open access 05 October 2023 Pages: 4457 - 4470
Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma Lisa May Ling TachikiDaniel S. HippeShailender Bhatia Correction Open access 18 November 2023 Pages: 4471 - 4471
